Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
Benda M, Mutschlechner B, Ulmer H, Grabher C, Severgnini L, Volgger A, Reimann P, Lang T, Atzl M, Huynh M, Gasser K, Petrausch U, Fraunberger P, Hartmann B, Winder T. Benda M, et al. Br J Haematol. 2021 Nov;195(4):523-531. doi: 10.1111/bjh.17743. Epub 2021 Aug 3. Br J Haematol. 2021. PMID: 34346068 Free PMC article.
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response.
Reimann P, Ulmer H, Mutschlechner B, Benda M, Severgnini L, Volgger A, Lang T, Atzl M, Huynh M, Gasser K, Grabher C, Mink S, Fraunberger P, Petrausch U, Hartmann B, Winder T. Reimann P, et al. Br J Haematol. 2022 Feb;196(3):577-584. doi: 10.1111/bjh.17982. Epub 2021 Dec 6. Br J Haematol. 2022. PMID: 34872162 Clinical Trial.
SARS-CoV-2 RBD-specific and NP-specific antibody response of healthcare workers in the westernmost Austrian state Vorarlberg: a prospective cohort study.
Atzl M, Muendlein A, Winder T, Fraunberger P, Brandtner EM, Geiger K, Klausberger M, Duerkop M, Sprenger L, Mutschlechner B, Volgger A, Benda M, Severgnini L, Jaeger JB, Drexel H, Lang A, Leiherer A. Atzl M, et al. BMJ Open. 2022 May 24;12(5):e052130. doi: 10.1136/bmjopen-2021-052130. BMJ Open. 2022. PMID: 35613821 Free PMC article.
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
Reimann P, Petzer V, Mündlein A, Hartmann B, Severgnini L, Winkler A, Lang T, Huynh M, Gasser K, Rüger J, Atzl M, Mink S, Fraunberger P, Schmidt S, Steiner N, Griesmacher A, Gunsilius E, Nachbaur D, Willenbacher W, Wolf D, Winder T, Benda MA. Reimann P, et al. Among authors: benda ma. Ann Hematol. 2024 Jun;103(6):2123-2131. doi: 10.1007/s00277-024-05671-6. Epub 2024 Mar 2. Ann Hematol. 2024. PMID: 38436671
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C, Mundl H, Patel MR; PACIFIC-AF Investigators. Piccini JP, et al. Lancet. 2022 Apr 9;399(10333):1383-1390. doi: 10.1016/S0140-6736(22)00456-1. Epub 2022 Apr 3. Lancet. 2022. PMID: 35385695 Clinical Trial.